



Luxembourg, 28 July 2023

Environmental and Social Completion Sheet (ESCS)

Overview

Project Name:	INNOVATIVE CELL THERAPIES (EGFF) (COVID-19)
Project Number:	2019-0880
Country:	Germany
Project Description:	The promoter is a clinical-stage biotherapy company that use placental cells and its unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, muscle injuries, haematological disorders and mucosal repair following a severe infection, as well as complications from COVID-19 infection.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

No significant environment or social issues were noted. The project concerned investments in research and development activities carried out in existing facilities already authorised for that purpose. Overall, the project has been assessed as acceptable, having no adverse impact on the environment.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on reports from the promoter that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.